Literature DB >> 22441305

Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands.

Ineke van Dis1, Johanna M Geleijnse, Jolanda Ma Boer, Daan Kromhout, Hendriek Boshuizen, Diederick E Grobbee, Yvonne T van der Schouw, Wm Monique Verschuren.   

Abstract

AIMS: European physicians use SCORE risk charts to predict a patient's 10-year risk of cardiovascular diseases (CVD) mortality. We examined whether the inclusion of nonfatal events improved risk estimation and the identification of high-risk persons. METHODS AND
RESULTS: In the EPIC-NL cohort, risk factor data were collected between 1993 and 1997 in 6772 men and 9108 women aged 35-65 years. During 10 years of follow up, 540 total (fatal + nonfatal) CVD events occurred, of which 122 (23%) were fatal. Risk equations were developed using Cox proportional hazard models. Discriminating ability and hazard ratios for CVD risk factors did not differ between the two endpoints. Absolute risks for total CVD were approximately 4-fold higher than for CVD mortality. Using the current 5% CVD mortality threshold or the 22% total CVD threshold for identification of high-risk persons leaves more than 84% of all male and 98% of all female future cases untreated. Of those exceeding these thresholds, 20% and 27% of the men, respectively, and 16% and 19% of women will get a CVD event in the next 10 years. Cut-off points of 2% for CVD mortality, corresponding to 10% for total CVD, will identify high-risk persons of whom approximately 10% will get an event in the next 10 years.
CONCLUSION: CVD mortality comprises a quarter of all total CVD events. Risk functions and the discriminating ability did not differ between the two endpoints. Cut-off points of 2% for CVD mortality or 10% for total CVD could be considered to identify high-risk persons.

Entities:  

Keywords:  Cardiovascular diseases; cardiovascular mortality; risk discrimination; risk estimation; risk factors

Mesh:

Year:  2012        PMID: 22441305     DOI: 10.1177/2047487312443485

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  8 in total

1.  2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).

Authors:  Massimo F Piepoli
Journal:  Int J Behav Med       Date:  2017-06

2.  Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.

Authors:  Luca Navarini; Damiano Currado; Annalisa Marino; Stefano Di Donato; Alice Biaggi; Francesco Caso; Luisa Costa; Marco Tasso; Piero Ruscitti; Viktoriya Pavlych; Onorina Berardicurti; Antonio Ciancio; Ilenia Pantano; Federica Camarda; Maria Sole Chimenti; Arianna D'Antonio; Francesco Ursini; Addolorata Corrado; Francesco Paolo Cantatore; Roberto Perricone; Giuliana Guggino; Francesco Ciccia; Paola Cipriani; Raffaele Scarpa; Antonella Afeltra; Roberto Giacomelli
Journal:  Sci Rep       Date:  2022-05-07       Impact factor: 4.996

3.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

4.  Trends in Cardiovascular Disease Risk Factor Prevalence and Estimated 10-Year Cardiovascular Risk Scores in a Large Untreated French Urban Population: The CARVAR 92 Study.

Authors:  Carma Karam; Alain Beauchet; Sebastien Czernichow; Florence de Roquefeuil; Alain Bourez; Nicolas Mansencal; Olivier Dubourg
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

5.  Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models.

Authors:  Grunde Wibetoe; Joseph Sexton; Eirik Ikdahl; Silvia Rollefstad; George D Kitas; Piet van Riel; Sherine Gabriel; Tore K Kvien; Karen Douglas; Aamer Sandoo; Elke E Arts; Solveig Wållberg-Jonsson; Solbritt Rantapää Dahlqvist; George Karpouzas; Patrick H Dessein; Linda Tsang; Hani El-Gabalawy; Carol A Hitchon; Virginia Pascual-Ramos; Irazu Contreas-Yañes; Petros P Sfikakis; Miguel A González-Gay; Iris J Colunga-Pedraz; Dionicio A Galarza-Delgado; Jose Ramon Azpiri-Lopez; Cynthia S Crowson; Anne Grete Semb
Journal:  Arthritis Res Ther       Date:  2020-04-23       Impact factor: 5.156

6.  Position statement of the Interamerican Society of Cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017-2020.

Authors:  Fernando Wyss; Antonio Coca; Patricio Lopez-Jaramillo; Carlos Ponte-Negretti
Journal:  Int J Cardiol Hypertens       Date:  2020-07-15

7.  Yearly hypertension screening in women with a history of pre-eclampsia: a cost-effectiveness analysis.

Authors:  J T Drost; J P C Grutters; G-J van der Wilt; Y T van der Schouw; A H E M Maas
Journal:  Neth Heart J       Date:  2015-12       Impact factor: 2.380

8.  Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk.

Authors:  Harald T Jørstad; Ersen B Colkesen; S Matthijs Boekholdt; Jan G Tijssen; Nicholas J Wareham; Kay-Tee Khaw; Ron J Peters
Journal:  Heart       Date:  2015-08-10       Impact factor: 5.994

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.